Shanghai Rightongene Biotechnology Co Ltd. Stock Analysis 688217.SS

Shanghai Rightongene Biotechnology Co., Ltd. engages in the research and development, production, and sale of in vitro diagnostic products. The company is headquartered in Shanghai, Shanghai and currently employs 336 full-time employees. The company went IPO on 2021-05-17. The firm's main products include leukemia molecular diagnostic kits and lymphoma molecular diagnostic kits. The firm mainly provides precise gene and antigen testing services for patients with blood diseases, solid tumors and infectious diseases. The firm also provides scientific research services applied in basic research, disease typing, drug adaptability and target genetic testing. The firm mainly conducts its businesses within domestic market.